Paris, France and Hoersholm, Denmark/San Diego, California, June 4, 2010 - Red Herring announced its Top 100 Award in recognition of the leading private companies from Europe, celebrating these startups’ innovations and technologies across their respective industries.
“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Europe to the Top 100 Winners. We believe Santaris Pharma A/S embodies the vision, drive and innovation that define a successful entrepreneurial venture. Santaris Pharma A/S should be proud of its accomplishment, as the competition was very strong.”
Red Herring’s Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.
“We are pleased to be honored by Red Herring with this award,” said Søren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. “Using the broad utility and versatility of our proprietary Locked Nucleic Acid Drug Platform and Drug Discovery Engine, we remain committed to discovering and developing effective RNA-targeted therapies for patients with unmet medical needs for a range of diseases including infectious diseases, inflammatory diseases, metabolic disorders, cancer and rare genetic disorders.”
Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Europe.
About Santaris Pharma A/S
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company’s research and development activities focus on infectious diseases and metabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer and Shire plc. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information.
###